Nationwide Real-World Exclusive Enteral Nutrition Practice Over Time: Persistence of Use as Induction for Pediatric Crohn’s Disease and Emerging Combination Strategy With Biologics

Author:

Wands David I F123ORCID,Gianolio Laura1,Wilson David C13,Hansen Richard24,Chalmers Iain5,Henderson Paul13ORCID,Gerasimidis Konstantinos6ORCID,Russell Richard K13ORCID

Affiliation:

1. Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Children and Young People , Edinburgh , United Kingdom

2. Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children , Glasgow , United Kingdom

3. Child Life and Health, University of Edinburgh, Royal Hospital for Children & Young People , Edinburgh , United Kingdom

4. Child Health, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee , Dundee , United Kingdom

5. Department of Paediatric Gastroenterology, Hepatology and Clinical Nutrition, Royal Aberdeen Children’s Hospital , Aberdeen , United Kingdom

6. Human Nutrition, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow Royal Infirmary , Glasgow , United Kingdom

Abstract

Abstract Background Exclusive enteral nutrition (EEN) is the recommended first-line induction treatment in pediatric patients with active luminal Crohn’s disease (CD). We aimed to provide a nationwide overview of evolving EEN practices during an era of increasing biologic use. Methods We analyzed a prospectively identified nationwide cohort of newly diagnosed pediatric patients with CD in Scotland between January 1, 2015, and June 30, 2022. Patients who received EEN for any indication were divided into 6-monthly epochs and examined over time. Differences during the COVID-19 pandemic (March 16, 2020, to July 19, 2021) were examined. Data were retrospectively collected from electronic medical records: demographics, anthropometrics, concomitant treatments, aspects of EEN administration, and remission/response rates. Descriptive statistics and linear regression were used for analyses. Results A total of 649 patients with CD were identified (63% male; median age 12.6 [interquartile range, 10.8-14.8] years); 497 (77%) of 649 received EEN as postdiagnosis induction therapy with a median course length of 7.7 (interquartile range, 5.9-8.0) weeks. Including repeat courses, 547 EEN courses were examined. An increasing incidence of CD was observed over time with no significant changes in EEN usage, remission or response rates, nasogastric tube usage, or course completion (all P > .05). Increasing use of EEN combined with biologics (combination induction) as first-line induction was observed over time (P < .001). Considering COVID-19, lower rates of EEN usage were observed (P = .008) with no differences in remission, oral administration, and course completion rates (all P > .05). Conclusions Over the past 7.5 years, except during the COVID-19 pandemic, EEN usage rates have not changed despite an increase in biologic use, although combination induction is an emerging trend.

Funder

Edinburgh Children’s Hospital Charity research fellowship

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3